Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

NCT04998136 on ClinicalTrials.gov · last registry update 2025-12-30

A small phase 3 — 150 participants, against a typical 424. The sponsor logged completion for 16 October 2023. Primary outcome, as filed: Change in Body Weight (%) : In-trial Observation Period. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 150
Started: 2022-08-15
Primary completion: 2023-10-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Body Weight (%) : In-trial Observation Period

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.